Jacobio Pharmaceuticals Group Co., Ltd. disclosed that it repurchased 97,800 ordinary shares on 23 July 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices ranging from HK$5.03 to HK$5.12, representing a volume-weighted average cost of HK$5.08 per share and a total consideration of HK$0.50 million.

\n\nFollowing the repurchase, the number of treasury shares increased from 9.38 million to 9.48 million, while issued shares outstanding (excluding treasury shares) fell marginally to 782.28 million. The change represents 0.0125 % of the company’s issued share capital before the transaction. Total issued shares, including treasury shares, remained unchanged at 791.76 million.

\n\nThe buyback was conducted under a shareholder mandate approved on 05 June 2026, which authorises Jacobio Pharmaceuticals to repurchase up to 78.37 million shares. Cumulative repurchases under this mandate now stand at 1.45 million shares, equivalent to 0.18 % of the company’s issued share capital on the mandate date.

\n\nIn accordance with Hong Kong listing rules, Jacobio Pharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 22 August 2026.